Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis (NYSE: ZTS) announced the launch of Lenivia (izenivetmab injection) in Canada and European Union member states. Lenivia is a long-acting monoclonal antibody therapy targeting nerve growth factor (NGF), designed to provide up to three months of osteoarthritis pain management for dogs with a single subcutaneous injection.
According to Zoetis, Lenivia showed sustained pain reduction from as early as Day 7 in a pivotal nine-month European field study. The product expands Zoetis’ osteoarthritis pain portfolio alongside Rimadyl, Trocoxil and Librela, supporting veterinarians and pet owners with an additional long-term pain management option for dogs.
Zoetis (NYSE:ZTS) announced an agreement to acquire VitalRADS, a veterinary teleradiology services platform, to strengthen its Global Diagnostics portfolio and advance an end-to-end Virtual Reference Lab. The acquisition builds on their August 2025 partnership and adds 24/7 cloud-based access to board-certified veterinary specialists across more than 25 species.
VitalRADS offers teleradiology, mobile ultrasound in Greater Houston and Greater Seattle, an outpatient imaging center in Cypress, Texas, and the VitalPACS cloud image storage platform. The business supports more than 1,800 active customers and is an American College of Veterinary Radiology certified residency program. Closing is expected in the third quarter of 2026, subject to customary conditions and regulatory approvals; financial terms were not disclosed.
Zoetis (NYSE:ZTS) received European Commission marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine for chickens.
The vaccine uses an HVT vector and in a single dose helps protect against Newcastle disease and Marek’s disease, administered in ovo or subcutaneously at hatch. Zoetis highlights benefits for EU poultry producers and export opportunities to southeast Asia.
Zoetis (NYSE:ZTS) will host a webcast and conference call to review its second quarter 2026 financial results at 8:30 a.m. ET on Thursday, August 6, 2026. CEO Kristin Peck and CFO Wetteny Joseph will discuss results and take analyst questions; webcast access and slides are via the Zoetis investor website, with replay available the same day.
Zoetis (NYSE:ZTS) released its 2025 Sustainability Report, showing progress under its Driven to Care strategy across Communities, Animals and Planet.
Highlights include $35 million in Zoetis Foundation grants from 2021–2025, 29% lower Scope 1 and 2 emissions since 2021, and 85% renewable electricity coverage in 2025.
Zoetis (NYSE:ZTS) will participate in upcoming investor conferences via fireside chats.
Events include the Stifel 2026 Jaws & Paws Conference on May 28, 2026 at 3:00 p.m. ET and the William Blair 46th Annual Growth Stock Conference on June 2, 2026 at 1:20 p.m. CT. Live and replay webcasts will be available on the Zoetis investor website.
Zoetis (NYSE:ZTS) announced its third quarter 2026 dividend. The Board declared a cash dividend of $0.53 per share, payable on September 1, 2026 to shareholders of record as of the close of business on July 20, 2026.
Zoetis (NYSE:ZTS) reported Q1 2026 revenue of $2.3B (+3% reported, flat organic) and net income of $601M ($1.42 diluted). Adjusted net income was $646M ($1.53 adjusted diluted EPS). The company revised 2026 guidance to $9.68B–$9.96B revenue and adjusted EPS $6.85–$7.00. U.S. revenue fell 8%; International grew 17% reported. Zoetis agreed to acquire Neogen’s animal genomics business and completed a fiscal year alignment effective Jan 1, 2026.
Zoetis (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. ET on Thursday, May 7, 2026 to review first quarter 2026 financial results. CEO Kristin Peck and EVP & CFO Wetteny Joseph will present and take questions from financial analysts.
Investors may access the live webcast and slides via the company investor website; pre-registration opens today and a replay will be posted on May 7, 2026.
Zoetis (NYSE:ZTS) announced that CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 10:30 a.m. ET. Interested parties can listen via a live audio webcast with a replay available on the company website.